Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 22;10(6):1303.
doi: 10.3390/jcm10061303.

Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review

Francesco Bartoli  1 , Ilaria Riboldi  1 , Bianca Bachi  1 , Angela Calabrese  1 , Federico Moretti  1 , Cristina Crocamo  1 , Giuseppe Carrà  1   2
Affiliations
Review

Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review

Francesco Bartoli et al. J Clin Med. .

Abstract

Although cannabis' major psychoactive component, Δ-9-tetrahydrocannabinol (THC), has been linked to both earlier onset and poorer outcomes of psychotic disorders, Cannabidiol (CBD) seems to have different pharmacological mechanisms and potential therapeutic properties. However, no clinical study has investigated CBD for the treatment of co-occurring psychotic and cannabis use disorders so far, even though its utility seems grounded in a plausible biological basis. The aim of this work is thus to provide an overview of available clinical studies evaluating the efficacy of CBD for psychotic symptoms induced by THC, schizophrenia, and cannabis use disorders. After searching for relevant studies in PubMed, Cochrane Library, and ClinicalTrials.gov, we included 10 clinical studies. Available evidence suggests that CBD may attenuate both psychotic-like symptoms induced by THC in healthy volunteers and positive symptoms in individuals with schizophrenia. In addition, preliminary data on the efficacy of CBD for cannabis use disorders show mixed findings. Evidence from ongoing clinical studies will provide insight into the possible role of CBD for treating psychotic and cannabis use disorders.

Keywords: Cannabidiol; cannabis use disorder; dual diagnosis; psychotic disorders; schizophrenia; Δ-9-tetrahydrocannabinol.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

See all similar articles

Cited by

References

    1. WHO, World Drug Report 2020. [(accessed on 18 January 2021)]; Available online: https://wdr.unodc.org/wdr2020/index.html.
    1. European Monitoring Centre for Drugs and Drug Addiction . European Drug Report 2020: Trends and Developments. Publication Office of the European Union; Luxembourg: 2020. - DOI
    1. Compton W.M., Han B., Jones C.M., Blanco C. Cannabis use disorders among adults in the United States during a time of increasing use of cannabis. Drug Alcohol Depend. 2019;204:107468. doi: 10.1016/j.drugalcdep.2019.05.008. - DOI - PMC - PubMed
    1. Carrà G., Crocamo C., Borrelli P., Popa I., Ornaghi A., Montomoli C., Clerici M. Correlates of dependence and treatment for substance use among people with comorbid severe mental and substance use disorders. Compr. Psychiatry. 2015;58:152–159. doi: 10.1016/j.comppsych.2014.11.021. - DOI - PubMed
    1. Carrà G., Johnson S., Crocamo C., Angermeyer M.C., Brugha T., Azorin J.-M., Toumi M., Bebbington P.E. Psychosocial functioning, quality of life and clinical correlates of comorbid alcohol and drug dependence syndromes in people with schizophrenia across Europe. Psychiatry Res. 2016;239:301–307. doi: 10.1016/j.psychres.2016.03.038. - DOI - PubMed

LinkOut - more resources